https://glpverdict.com/news/wegovy-hd-approved-2026-q2 Glpverdict en 2026-05-15T10:00:00Z FDA approves Wegovy HD — higher-dose semaglutide for sustained weight loss https://glpverdict.com/news/mdl-3094-bellwether-trial-set-2026 Glpverdict en 2026-05-22T10:00:00Z MDL-3094 gastroparesis litigation: first bellwether trials scheduled for Q4 2026 https://glpverdict.com/news/nice-ta1026-tirzepatide-uk-expansion-2026 Glpverdict en 2026-05-28T10:00:00Z NICE expands tirzepatide weight-management eligibility in England (TA1026 update) https://glpverdict.com/news/foundayo-orforglipron-launch-q2-2026 Glpverdict en 2026-05-06T10:00:00Z Foundayo (orforglipron) — first oral non-peptide GLP-1 — launches in US https://glpverdict.com/news/compounded-semaglutide-ban-2026 Glpverdict en 2026-05-24T10:00:00Z Is compounded semaglutide still legal in 2026? FDA 503B rule update https://glpverdict.com/news/fda-glp1-approvals-timeline Glpverdict en 2026-05-24T10:00:00Z FDA GLP-1 approval timeline 2017-2026: every drug, every milestone